A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse

Journal of Pharmaceutical Sciences

Volumn 97, Issue 11, 2008, Pages 5013-5023

  Shen, Jun ^a,b   Fraga, Charles ^a   Calabrese, Christopher ^a   Mccarville, M Beth ^a   Schaiquevich, Paula ^a   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Blood CSF barrier; Lateral ventricle; Microdialysis; Pharmacokinetics; Surgical technique; Topotecan

Indexed keywords

GEFITINIB; TOPOTECAN;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN VENTRICLE; CEREBROSPINAL FLUID; COMPUTER ASSISTED TOMOGRAPHY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG PENETRATION; FEMALE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; SURGICAL TECHNIQUE; ULTRASOUND;

EID: 52649141256     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21332     Document Type: Article

References (24)

1. Benveniste H, Huttemeir PC. 1990. Microdialysis-Theory and application. Prog Neurobiol 35:195-215.
2. Boschi G, Scherrmann J. 2000. Microdialysis in mice for drug delivery research. Adv Drug Deliv Rev 45:271-281.
3. Bito L, Davson H, Levin E, Murray M, Snider N. 1966. The concentrations of free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog. J Neurochem 13:1057-1067.
4. Meirieu O, Pairet M, Sutra JF, Ruckebusch M. 1986. Local release of monoamines in the gastrointestinal tract: An in vivo study in rabbits. Life Sci 38:827-834.
5. Lehmann A. 1989. Effects of microdialysis-perfusion with anisoosmotic media on extracellular amino acids in the rat hippocampus and skeletal muscle. J Neurochem 53:525-535.
6. Arner P, Bolinder J, Eliasson A, Lundin A, Ungerstedt U. 1988. Microdialysis of adipose tissue and blood for in vivo lipolysis studies. Am J Physiol 255:E737-E742.
7. Ben-Nun J, Cooper RL, Cringle SJ, Constable IJ. 1988. Ocular dialysis. A new technique for in vivo intraocular pharmacokinetic measurements. Arch Ophthalmol 106:254-259.
8. Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF. 2006. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Res 66:11305-11313.
9. Jonker JW, Freeman J, Bolscher E, Musters S, Alvi AJ, Titley I, Schinkel AH, Dale TC. 2005. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 23:1059-1065.
10. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. 2002. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654.
11. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van DL, Smit JJ, van der Valk MA, Voordouw AC, Spits H, Van TO, Zijlmans JM, Fibbe WE, Borst P. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
12. Franklin KB. 1997. The mouse brain in stereotaxic coordinates.
13. Leggas M, Zhuang Y, Welden J, Self Z, Waters CM, Stewart CF. 2004. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. J Pharm Sci 93:2284-2295.
14. Hammarlund-Udenaes M, Paalzow LK, de Lange EC. 1997. Drug equilibration across the blood-brain barrier - Pharmacokinetic considerations based on the microdialysis method. Pharm Res 14:128-134.
15. D'Argenio DZ, Schumitzky A. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Program Biomed 9:115-134.
16. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. 1993. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 53:725-727.
17. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM. 1998. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 41:464-468.
18. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844-8853.
19. Haley TJ, Mccormick WG. 1957. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12:12-15.
20. Clark WG, Vivonia CA, Baxter CF. 1968. Accurate freehand injection into the lateral brain ventricle of the conscious mouse. J Appl Physiol 25:319-321.
21. Boschi G, Launay N, Rips R. 1981. Implantation of an intracerebral cannula in the mouse. J Pharmacol Methods 6:193-198.
22. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. 2004. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491-7499.
23. LeggasM, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, StewartCF. 2006. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 66:4802-4807.
24. Johanson CE, Duncan JA, Stopa EG, Baird A. 2005. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22:1011-1037.